TABLE 3.

Treatment

Characteristic	All	Schedule A	Schedule B
Induction cycles
Median	4	4	4
Range	1–9	1–8	1–9
Maintenance cycles
No of patients (%)	16 (37.2)	12 (52.2)	4 (20)
Talazoparib/carboplatin
No of patients (%) a	6 (13.9)	4 (17.4)	2 (10)
Median cycles	2	3.5	2
Range	2–9	2–9	2–2
Talazoparib monotherapy
No of patients (%) a	13 (30.2)	9 (39.1)	2 (10)
Median cycles	8	15	10
Range	1–63	1–63	2–18
Dose modification at MTD (No of patients, %)
Ever	27 (96.4)	14 (93)	13 (100)
During induction	27 (96.4)	14 (93)	13 (100)
Chemotherapy dose reduction	27 (96.4)	14 (93)	13 (100)
BMN dose reduction	1 (3.5)	1 (7)	0 (0)
Induction % dose intensity at MTD (mean, SD) b
Carboplatin	91 (9)	93 (7)	89 (10)
Paclitaxel	68 (17)	69 (18)	68 (17)
BMN	92 (20)	89 (24)	94 (14)
Supportive care (No of patients, %)
Growth factor	15 (34.8)	11 (47.8)	4 (20)
Any transfusion	14 (32.5)	6 (26.1)	8 (40)
pRBC transfusion	12 (27.9)	6 (26.1)	6 (30)
Platelet transfusion	2 (4.6)	0 (0)	2 (10)
Reason for treatment discontinuation (No of patients, %)
Disease progression	26 (60.4)	14 (60.8)	12 (60)
Adverse event	5 (11.6)	3 (13)	2 (10
Intercurrent illness	3 (6.9)	1 (4.3)	2 (10)
Death on study	1 (2.3)	0 (0)	1 (5)
Study completion/transition to commercial drug	2 (4.66)	2 (8.7)	0 (0)
Other	6 (13.9)	3 (13) c	3 (15) d

^a Patients who received both talazoparib/carboplatin and subsequent talazoparib monotherapy maintenance are reported in both groups.

^b Percent of full dose based on number of induction cycles.

^c Schedule A (one patient each): Physician's decision, Patient not tolerating therapy, and Switched to alternative treatment.

^d Schedule B (one patient each): Refused further treatment, late determination of eligibility, and treatment held for more than 3 weeks.